Acute Effects of Cold Exposure on Cognitive Function
NCT06654167, Not applicable, Active not recruiting, Fudan University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Acute Effects of Cold Exposure on Cognitive Function | ClinicalTrials.gov |
| NCT number | NCT06654167 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Fudan University | ClinicalTrials.gov |
| Conditions | Cognitive Function | ClinicalTrials.gov |
| Interventions | Low temperature (15℃) group, Moderate temperature (22℃) group | ClinicalTrials.gov |
| First posted | 2024-10-23 | ClinicalTrials.gov |
| Last updated | 2025-02-27 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Results of Stroop Tests | before exposure and immediately after the exposure session | Investigators plan to measure the changes of cognitive function using Stroop Test. The time taken to complete the test could reflect cognitive function, and a shorter time means better cognitive function. | ClinicalTrials.gov |
| Secondary | Results of simple reaction time | before exposure and immediately after the exposure session | Investigators plan to measure the changes of cognitive function using visual memory test | ClinicalTrials.gov |
| Secondary | Activated brain regions demonstrating neural activity related to the high temperature exposure | 1 hour after exposure session | Investigators plan to measure brain activity associated with high temperature exposure by magnetic resonance imaging (MRI). Brain imaging data will be extracted from MRI data. The fractional amplitude of low frequency fluctuation (fALFF) would be extracted to reflect neural activity of brain regions. | ClinicalTrials.gov |
| Secondary | Activated brain regions demonstrating neural connectivity related to the high temperature exposure | 1 hour after exposure session | Investigators plan to measure brain activity associated with high temperature exposure by magnetic resonance imaging (MRI). Brain imaging data will be extracted from MRI data. The degree of centrality (DC) would be extracted to reflect neural connectivity of brain regions. | ClinicalTrials.gov |
| Secondary | Activated brain regions demonstrating neural synchronization related to the high temperature exposure | 1 hour after exposure session | Investigators plan to measure brain activity associated with high temperature exposure by magnetic resonance imaging (MRI). Brain imaging data will be extracted from MRI data. The regional homogeneity (ReHo) would be extracted to reflect neural synchronization of brain regions. | ClinicalTrials.gov |
| Secondary | Changes of skin temperature | Skin temperature will be examined during the 2-hour exposure session (i.e., 1:00 P.M. to 3:00 P.M. on the day of the exposure session) | The changes of wrist skin temperature will be measured | ClinicalTrials.gov |
| Other | Differences in RNA expression levels detected in serum transcriptomics between the two exposures | 1 hour after the exposure session | Illumina-based transcriptomics is non-targeted. The study is to find the differentially expressed exosome RNA in serum after low temperature exposure | ClinicalTrials.gov |
| Other | Change in brain-derived neurotrophic factor (BDNF) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of BDNF in blood. | ClinicalTrials.gov |
| Other | Change in glial cell line-derived neurotrophic factor (GDNF) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of GDNF in blood. | ClinicalTrials.gov |
| Other | Change in γ-aminobutyric acid (GABA) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of GABA in blood. | ClinicalTrials.gov |
| Other | Change in Interleukin-1β (IL-1β) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of IL-1β in blood. | ClinicalTrials.gov |
| Other | Change in Interferon-β (IFN-β) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of IFN-β in blood. | ClinicalTrials.gov |
| Other | Change in glutathione (GSH) concentrations | 1:00 P.M. on the day of the exposure session, 1 hour after the exposure session | Change in the concentrations of GSH in blood. | ClinicalTrials.gov |
| Other | Changes of the scores of thermal sensation questionnaires | before exposure and immediately after the exposure session | Changes of scores of thermal sensation questionnaires which ranged from -5 to 5. Zero score refers to the thermal comfort sensation. Higher scores refer to more uncomfortable sensations of hot. Lower scores refer to more uncomfortable sensations of cold. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Simple Reaction Time | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)